Study: Oncology accelerated approvals are often based on non-comparative trials evaluating response rate
Regulatory NewsJeff Craven
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesClinical TrialsExpedited pathwaysPharmaceuticalsPostmarketing requirement/postmarketing commitmentProduct LifecycleUnited States